Regeneron Pharmaceuticals Inc  

(Public, NASDAQ:REGN)   Watch this stock  
Find more results for REGN
-0.85 (-0.23%)
Jan 20 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 362.07 - 369.98
52 week 325.35 - 484.57
Open 365.67
Vol / Avg. 781,954.00/1.01M
Mkt cap 38.20B
P/E 52.81
Div/yield     -
EPS 6.87
Shares 103.56M
Beta 1.80
Inst. own 72%
Feb 7, 2017
Q4 2016 Regeneron Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Jan 9, 2017
Regeneron Pharmaceuticals Inc at JPMorgan Healthcare Conference - Q&A
Jan 9, 2017
Regeneron Pharmaceuticals Inc at JPMorgan Healthcare Conference
Nov 8, 2016
Regeneron Pharmaceuticals Inc at Credit Suisse Healthcare Conference
Nov 4, 2016
Q3 2016 Regeneron Pharmaceuticals Inc Earnings Release
Nov 4, 2016
Q3 2016 Regeneron Pharmaceuticals Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin 21.70% 15.50%
Operating margin 29.73% 30.05%
EBITD margin - 32.33%
Return on average assets 16.30% 13.47%
Return on average equity 24.79% 20.50%
Employees 4,300 -
CDP Score - 59 E


777 Old Saw Mill River Rd
TARRYTOWN, NY 10591-6717
United States - Map
+1-914-3477000 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company's segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions. It commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol and a rare inflammatory condition, and has product candidates in development in other areas of unmet medical need, including oncology, rheumatoid arthritis (RA), asthma, atopic dermatitis, pain and infectious diseases. Its marketed products include EYLEA (aflibercept) injection, Praluent (alirocumab) Injection and ARCALYST (rilonacept) injection for subcutaneous use. Its other products include Sarilumab (REGN88), Dupilumab (REGN668), REGN2222, Fasinumab (REGN475), REGN2810, REGN2176-3, Evinacumab (REGN1500) and REGN1908-1909.

Officers and directors

P. Roy Vagelos M.D. Chairman of the Board
Age: 86
Bio & Compensation  - Reuters
Leonard S. Schleifer M.D., Ph.D. President, Chief Executive Officer, Director
Age: 63
Bio & Compensation  - Reuters
Robert E. Landry Chief Financial Officer, Senior Vice President - Finance
Age: 52
Bio & Compensation  - Reuters
Daniel P. Van Plew Executive Vice President, General Manager - Industrial Operations and Product Supply
Age: 43
Bio & Compensation  - Reuters
Neil Stahl Ph.D. Executive Vice President - Research and Development
Age: 59
Bio & Compensation  - Reuters
Robert J. Terifay Executive Vice President - Commercial
Age: 56
Bio & Compensation  - Reuters
Joseph J. LaRosa Senior Vice President, General Counsel, Secretary
Age: 57
Bio & Compensation  - Reuters
Michael Aberman M.D. Senior Vice President - Strategy and Investor Relation
Age: 45
Bio & Compensation  - Reuters
Jay S. Markowitz M.D. Senior Vice President - Portfolio Management
Bio & Compensation  - Reuters
Peter Powchik M.D. Senior Vice President - Clinical Development
Age: 59
Bio & Compensation  - Reuters